Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Stein

Showing results (521-530 of 576) with videos related to

Pageof 58
Sort By:
The American Journal of Orthopsychiatry|February 18, 2025
Perspectives on a system-oriented trauma-informed approach in schools: A qualitative study using the Trauma-Informed Programs and Practices for Schools (TIPPS) frameworkHurley O Riley, Alison L Miller, Yujeong Chang, et al.
Journal of Health Psychology|August 17, 2017
Exploring changes in distress among individuals with bleeding disorders: What is linked to improvements in distress?Vaughn Barry, Mary Ellen Lynch, Duc Q Tran, et al.
Dermatology and Therapy|April 4, 2026
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative ReviewApril W Armstrong, James G Krueger, Bruce E Strober, et al.
Radiation Oncology (London, England)|April 27, 2013
Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT)Marsha Reyngold, Abraham J Wu, Amanda McLane, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Journal of the American Academy of Dermatology|May 19, 2016
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled studyJon M Hanifin, Charles N Ellis, Ilona J Frieden, et al.
Health Promotion Practice|May 9, 2022
Parenting and Lead Mitigation at Home: A Multifaceted Community Partnership Model Promoting Parent Engagement in Lead Exposure PreventionAlison L Miller, Rachel Varisco, Simone Charles, et al.
JACC. Cardiooncology|March 30, 2026
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular FailureHarveen Sekhon, Pradeep S Rajendran, Katherine Hampilos, et al.
Journal of the American Academy of Dermatology|August 22, 2017
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisLawrence F Eichenfield, Robert S Call, Douglass W Forsha, et al.
Plos One|June 8, 2012
MEG can map short and long-term changes in brain activity following deep brain stimulation for chronic painHamid R Mohseni, Penny P Smith, Christine E Parsons, et al.
Pageof 58

Showing results (521-530 of 576) with videos related to

Sort By:
Pageof 58
The American Journal of Orthopsychiatry|February 18, 2025
Perspectives on a system-oriented trauma-informed approach in schools: A qualitative study using the Trauma-Informed Programs and Practices for Schools (TIPPS) frameworkHurley O Riley, Alison L Miller, Yujeong Chang, et al.
Journal of Health Psychology|August 17, 2017
Exploring changes in distress among individuals with bleeding disorders: What is linked to improvements in distress?Vaughn Barry, Mary Ellen Lynch, Duc Q Tran, et al.
Dermatology and Therapy|April 4, 2026
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative ReviewApril W Armstrong, James G Krueger, Bruce E Strober, et al.
Radiation Oncology (London, England)|April 27, 2013
Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT)Marsha Reyngold, Abraham J Wu, Amanda McLane, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Journal of the American Academy of Dermatology|May 19, 2016
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled studyJon M Hanifin, Charles N Ellis, Ilona J Frieden, et al.
Health Promotion Practice|May 9, 2022
Parenting and Lead Mitigation at Home: A Multifaceted Community Partnership Model Promoting Parent Engagement in Lead Exposure PreventionAlison L Miller, Rachel Varisco, Simone Charles, et al.
JACC. Cardiooncology|March 30, 2026
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular FailureHarveen Sekhon, Pradeep S Rajendran, Katherine Hampilos, et al.
Journal of the American Academy of Dermatology|August 22, 2017
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisLawrence F Eichenfield, Robert S Call, Douglass W Forsha, et al.
Plos One|June 8, 2012
MEG can map short and long-term changes in brain activity following deep brain stimulation for chronic painHamid R Mohseni, Penny P Smith, Christine E Parsons, et al.
Pageof 58